LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 559

Search options

  1. Article: Maurie Markman on the Groundbreaking TAPUR Trial.

    Markman, Maurie

    Oncology (Williston Park, N.Y.)

    2017  Volume 31, Issue 3, Page(s) 158, 168

    MeSH term(s) Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Clinical Trials as Topic/methods ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Patient Selection ; Phenotype ; Precision Medicine ; Predictive Value of Tests ; Research Design ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Biomarkers, Tumor
    Language English
    Publishing date 2017-03-15
    Publishing country United States
    Document type Interview ; Portraits
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Online ; E-Book: Cancer consult

    Abutalib, Syed A. / Markman, Maurie / Armitage, James O. / Anderson, Kenneth C. / Rugo, Hope S. / Benson, Al B., III.

    solid tumors and supportive care

    2024  

    Language English
    Size 1 online resource (754 pages)
    Edition 2nd ed.
    Publisher John Wiley & Sons, Incorporated
    Publishing place Newark
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 1-119-82376-5 ; 1-119-82374-9 ; 9781119823735 ; 978-1-119-82376-6 ; 978-1-119-82374-2 ; 1119823730
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Book ; Online: Neoadjuvant Chemotherapy : Increasing Relevance in Cancer Management

    Markman, Maurie M.

    2013  

    Keywords Oncology
    Size 1 electronic resource (114 pages)
    Publisher IntechOpen
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021046562
    ISBN 9789535171546 ; 9535171542
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Book: Atlas of cancer

    Markman, Maurie

    2003  

    Title variant Cancer
    Author's details ed. Maurie Markman
    Keywords Neoplasms
    Language English
    Size XII, 628 S. : zahlr. Ill., graph. Darst.
    Publisher Lippincott Williams & Wilkins
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT013568850
    ISBN 0-7817-4280-3 ; 978-0-7817-4280-1
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2003 C 34 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Precision Cancer Medicine.

    Markman, Maurie

    MD advisor : a journal for New Jersey medical community

    2019  Volume 11, Issue 1, Page(s) 4–6

    Language English
    Publishing date 2019-09-09
    Publishing country United States
    Document type Journal Article
    ISSN 1947-3613
    ISSN (online) 1947-3613
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Cancer in Women.

    Markman, Maurie

    Journal of women's health (2002)

    2019  Volume 28, Issue 2, Page(s) 236

    MeSH term(s) Breast Neoplasms ; Female ; Genital Neoplasms, Female ; Humans
    Language English
    Publishing date 2019-04-01
    Publishing country United States
    Document type Introductory Journal Article
    ZDB-ID 1139774-3
    ISSN 1931-843X ; 1059-7115 ; 1540-9996
    ISSN (online) 1931-843X
    ISSN 1059-7115 ; 1540-9996
    DOI 10.1089/jwh.2019.7656
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3584: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Lenvatinib Real-Life Experience.

    Markman, Maurie

    Oncology

    2019  Volume 97, Issue 4, Page(s) 189–190

    MeSH term(s) Humans ; Phenylurea Compounds ; Quinolines ; Thyroid Neoplasms
    Chemical Substances Phenylurea Compounds ; Quinolines ; lenvatinib (EE083865G2)
    Language English
    Publishing date 2019-08-07
    Publishing country Switzerland
    Document type Editorial ; Comment
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    DOI 10.1159/000501641
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The Evolving Arena of Ovarian Cancer Maintenance Therapy.

    Markman, Maurie

    Oncology

    2019  Volume 97, Issue 4, Page(s) 202–205

    Abstract: Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While ... ...

    Abstract Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support for this therapeutic concept in disease management (e.g., multiple cycles of single-agent paclitaxel following a clinical complete response to a platinum/paclitaxel regimen), more recent data has revealed both the efficacy and safety of the anti-angiogenesis agent, bevacizumab, and several PARP inhibitors when employed in this clinical setting.
    MeSH term(s) Bevacizumab/administration & dosage ; Drug Therapy/methods ; Female ; Humans ; Medical Oncology/trends ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/immunology ; Paclitaxel/administration & dosage ; Platinum/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors ; Bevacizumab (2S9ZZM9Q9V) ; Platinum (49DFR088MY) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2019-07-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 250101-6
    ISSN 1423-0232 ; 0030-2414
    ISSN (online) 1423-0232
    ISSN 0030-2414
    DOI 10.1159/000501618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Genomic-Based Therapy of Gynecologic Malignancies.

    Markman, Maurie

    Acta medica academica

    2019  Volume 48, Issue 1, Page(s) 84–89

    Abstract: This paper will review the current status of genomic-based therapy of gynecologic malignancies. The routine "standard-of-care" delivery of targeted therapeutics based on the presence of specific molecular biomarkers in the management of the gynecologic ... ...

    Abstract This paper will review the current status of genomic-based therapy of gynecologic malignancies. The routine "standard-of-care" delivery of targeted therapeutics based on the presence of specific molecular biomarkers in the management of the gynecologic malignancies has been delayed compared to the substantial progress made in several other tumor types. However, relatively recently reported and rather robust phase 3 trial data have confirmed a potentially major role for PARP inhibitors as both active treatment and maintenance therapy of advanced ovarian cancer. Further, data demonstrating the presence of a specific molecular phenotype (micro-satellite ( instability high - MSI-H) is a valid biomarker for the potential clinical utility of checkpoint inhibitor immunotherapy has relevance for all gynecologic malignancies, and particularly in the setting of metastatic or recurrent endometrial cancer. CONCLUSIONS: The introduction of PARP inhibitors into the oncology armamentarium has substantially impacted standard-of-care strategies in the management of ovarian cancer. It is anticipated that the results of ongoing and future trials will further define the role of genomic-based therapy in ovarian cancer and other gynecologic malignancies.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Endometrial Neoplasms/genetics ; Endometrial Neoplasms/therapy ; Female ; Genital Neoplasms, Female/genetics ; Genital Neoplasms, Female/therapy ; Genomics ; Humans ; Immunotherapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/therapy ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
    Chemical Substances Antineoplastic Agents ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2019-07-01
    Publishing country Bosnia and Herzegovina
    Document type Journal Article ; Review
    ZDB-ID 2558604-X
    ISSN 1840-2879 ; 1840-1848
    ISSN (online) 1840-2879
    ISSN 1840-1848
    DOI 10.5644/ama2006-124.245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Pharmaceutical Management of Ovarian Cancer: Current Status.

    Markman, Maurie

    Drugs

    2019  Volume 79, Issue 11, Page(s) 1231–1239

    Abstract: For more than 20 years, the combination of a platinum agent and a taxane has served as the primary chemotherapy strategy for epithelial ovarian cancer. Alternative approaches employing these drugs (intraperitoneal drug delivery, neoadjuvant therapy) have ...

    Abstract For more than 20 years, the combination of a platinum agent and a taxane has served as the primary chemotherapy strategy for epithelial ovarian cancer. Alternative approaches employing these drugs (intraperitoneal drug delivery, neoadjuvant therapy) have favorably impacted outcomes in selected patient populations. Multiple single agent and combination therapy strategies have been delivered in the second-line (or later) setting with the goal to prolong survival and optimize quality-of-life. The anti-angiogenic agent bevacizumab has been shown to be clinically active when added to chemotherapy and delivered as a "maintenance" strategy in the front-line, platinum-sensitive recurrent and platinum-resistant settings. Several poly-(ADP-ribose) polymerase (PARP) inhibitors are currently utilized as single-agent "second-line" treatment options or in the maintenance setting. Recent clinical research efforts in ovarian cancer have focused on the potential role of checkpoint inhibitors used alone or in combination with PARP inhibitors or anti-angiogenic agents.
    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/therapeutic use ; Bridged-Ring Compounds/therapeutic use ; Carboplatin/therapeutic use ; Carcinoma, Ovarian Epithelial/drug therapy ; Cisplatin/therapeutic use ; Drug Delivery Systems/methods ; Drug Resistance, Neoplasm ; Female ; Humans ; Neoadjuvant Therapy ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Poly(ADP-ribose) Polymerases/metabolism ; Taxoids/therapeutic use
    Chemical Substances Angiogenesis Inhibitors ; Antineoplastic Agents ; Bridged-Ring Compounds ; Poly(ADP-ribose) Polymerase Inhibitors ; Taxoids ; taxane (1605-68-1) ; Bevacizumab (2S9ZZM9Q9V) ; Carboplatin (BG3F62OND5) ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30) ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2019-07-02
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-019-01158-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 762: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top